The retrospective finding of relatively higher benefit of Luminal B BCs patients to ribocilib in the MONALESSA trials (78), offers the possibility of stratifying genomically high-risk, cell-cycle driven PCa patients to CDK4/6 inhibitors. The gene discussed is CDK4; the disease is posterior cortical atrophy.